Performances of the VitaPCR™ SARS‐CoV‐2 Assay during the second wave of the COVID‐19 epidemic in France
Finally, our observations confirm high usability and go […]
日期: 2021 年 4 月 1 日
Finally, our observations confirm high usability and go […]
Focusing on research and development of revolutionary diagnostic technologies since 2011, Credo Diagnostics develops, manufactures, and commercializes accurate, rapid, and affordable molecular diagnostic solutions at the Point-Of-Care testing.
© 2023 | Credo Diagnostics Biomedical Pte. Ltd.
